Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Günter Klöppel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6688-086X; OpenAlex author ID A5089124733. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
79
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 15

  1. Pancreatic Neuroendocrine Tumor with Acinar Pattern Mimicking Pancreatic Ductal Adenocarcinoma: A Case Report. Co-author DOI 10.70352/scrj.cr.26-0184↗
  2. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  3. Utility of pVHL, maspin, IMP3, S100P and Ki67 in the distinction of autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.prp.2020.152925↗
  4. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  5. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  6. The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. Co-author DOI 10.3390/jcm7100295↗
  7. Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
  8. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  9. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2014.05.007↗
  10. [IgG4-related systemic disease with autoimmune pancreatitis and lung involvement primarily presenting as pancreatic cancer with pulmonary metastases]. First author DOI 10.1055/s-0032-1330533↗
  11. Variation in precursor lesions of pancreatic cancer among high-risk groups. Co-author DOI 10.1158/1078-0432.ccr-12-2730↗
  12. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.26502↗
  13. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. Co-author DOI 10.1002/path.3017↗
  14. [New insights into the origin of pancreatic cancer. Role of atypical flat lesions in pancreatic carcinogenesis]. Last author DOI 10.1007/s00292-012-1673-x↗
  15. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Co-author DOI 10.1016/j.ccr.2011.03.009↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Iréne Esposito · 6 shared papers, 2012–2023 · strength 0.36
  2. Anna Melissa Schlitter · 3 shared papers, 2012–2023 · strength 0.26
  3. Atsuko Kasajima · 1 shared paper, 2026 · strength 0.25
  4. Kei Yamane · 1 shared paper, 2026 · strength 0.25
  5. Kazuyuki Nagai · 1 shared paper, 2026 · strength 0.25
  6. Etsuro Hatano · 1 shared paper, 2026 · strength 0.25
  7. Yasunori Shirakawa · 1 shared paper, 2026 · strength 0.25
  8. Shinya Okumura · 1 shared paper, 2026 · strength 0.25
  9. Detlef Klaus Bartsch · 6 shared papers, 2012–2018 · strength 0.24
  10. Emily P. Slater · 5 shared papers, 2013–2018 · strength 0.22
  11. Andreas Trumpp · 2 shared papers, 2018–2023 · strength 0.21
  12. Peter Langer · 5 shared papers, 2012–2016 · strength 0.18
  13. Jens Thomas Siveke · 2 shared papers, 2012–2023 · strength 0.18
  14. Sven‐Thorsten Liffers · 1 shared paper, 2023 · strength 0.15
  15. Elisa Espinet · 1 shared paper, 2023 · strength 0.15
  16. Nikolas Hendrik Stoecklein · 1 shared paper, 2023 · strength 0.15
  17. Aslihan Yavas · 1 shared paper, 2023 · strength 0.15
  18. Lena Häberle · 1 shared paper, 2023 · strength 0.15
  19. Laura Godfrey · 1 shared paper, 2023 · strength 0.15
  20. Wolfram Trudo Knoefel · 1 shared paper, 2023 · strength 0.15
  21. Gitte Hedegaard Jensen · 1 shared paper, 2020 · strength 0.13
  22. Michael Friberg Bruun Nielsen · 1 shared paper, 2020 · strength 0.13
  23. Michael Bau Mortensen · 1 shared paper, 2020 · strength 0.13
  24. Sönke Detlefsen · 1 shared paper, 2020 · strength 0.13
  25. Volker Fendrich · 3 shared papers, 2014–2016 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.